Swedish Orphan Biovitrum AB Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: October 15, 2016
Pages: 50
US$ 499.00
Swedish Orphan Biovitrum AB Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Swedish Orphan Biovitrum AB Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Swedish Orphan Biovitrum AB Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Swedish Orphan Biovitrum AB and its competitors. This provides our Clients with a clear understanding of Swedish Orphan Biovitrum AB position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Swedish Orphan Biovitrum AB that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Swedish Orphan Biovitrum AB. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Swedish Orphan Biovitrum AB financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Swedish Orphan Biovitrum AB competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Swedish Orphan Biovitrum AB business.

About Swedish Orphan Biovitrum AB

Biovitrum AB, a biopharmaceutical company, engages in the development, manufacture, and sale of specialist pharmaceuticals. The company’s therapeutic focus is within hemophilia, supportive cancer care, inflammation/autoimmune diseases and malabsorption.

The company markets and sells medications to treat the two most common types of hemophilia in the Nordic market (hemophilia A and hemophilia B). It works on a contract basis and is the manufacturer of the active protein that is part of ReFacto.

The company markets the other medication, BeneFix (for the treatment of hemophilia B in the Nordic region through a cooperation agreement with Wyeth. The company is also developing tlongacting medications, which would simplify treatment for patients with hemophilia.

The company focuses on medications for patients with a medical need. This category includes specialist drugs, which are mainly prescribed by clinical specialists and aimed at small well-defined patient groups. Biovitrum has also several specialist drugs that belong to this category in the development portfolio.

The company, in 2008, established its marketing organization in Europe, USA, Canada, Australia and New Zealand through the acquisition of Kepivance, Stemgen, and Kineret. In addition, ReFacto and four additional products, Kineret, Mimpara, Aloxi and BeneFIX, are all marketed in the Nordic countries.

Portfolio of specialist care projects

Kepivance for the treatment of oral mucositis in children following cancer treatment: A clinical study with Kepivance is under way in which children with acute leukemia who have undergone a transplant of stem cells are being treated. The aim of the study, which includes approximately 27 children ages 1 to 16, is primarily to study safety and pharmacokinetics. The study is also registering the therapeutic effect on inflammation in the mouth and throat.

Exinalda for the treatment of fat malabsorption due to pancreatic insufficiency: A clinical phase II study with Exinalda has started. The aim of the study is to document the clinical effect of Exinalda in patients with pancreatic insufficiency as a result of cystic fibrosis. The study involves 18 patients and is being conducted in Poland and the Netherlands.

Kiobrina for the treatment of fat malabsorption in preterm Infants: Two parallel clinical phase II trials – one where rhBSSL is administered in pasteurized breast milk and one where it is administered in infant formula – are under way in Italy and France.

Anti-Rh(D) for the treatment of idiopathic thrombocytopenia purpura (ITP) and prophylaxis of Rh immunization: A phase I study has been concluded with good results. A clinical study which shows that Sym001 can eliminate RhD positive red blood cells from the circulation of RhD negative healthy volunteers has also been conducted. In addition, a clinical phase II study is ongoing to test the safety and therapeutic effect of Sym001 in IT P patients at 23 clinics in Europe.

Factor IX Fc (FIXFc) for the treatment of hemophilia B: A clinical phase I/II a study of FIX Fc with hemophilia B patients is ongoing. The study is being conducted at clinics in the U.S. and is testing the safety, tolerability and pharmacokinetics of FIX Fc in these patients.

Factor VIIIFc (FVIIIFc) for the treatment of hemophilia A: The project is in the preclinical phase.

Biovitrum’s portfolio of primary care projects

5-HT2A for the treatment of glaucoma: The preliminary results from the exploratory phase II study of the 5-HT 2A antagonist, BVT .28949, for the treatment of glaucoma have demonstrated a dose-dependent reduction of intraocular pressure.

A2A for the treatment of neuropathic pain: The project objective is to develop a new product with a mechanism of action for the treatment of neuropathic pain.

11ß-HSD1 for the treatment of diabetes: This project is outlicensed to Amgen which owns the rights to develop and commercialize the compounds. The project, which is being run by Amgen, is in clinical phase I.

5-HT6 for the treatment of obesity: Biovitrum has conducted a clinical phase I study of a 5-HT 6 antagonist for the treatment of obesity and a safe and tolerated dose has been identified. The company also has another five preclinical research programs. These include a Mnk inhibitor to treat type 2 diabetes, leptin mimetic and SC D inhibitors to treat obesity and 11ß-HS D1 to treat glaucoma.

Manufacturing and contract development

The company manufactures the active ingredient for ReFacto and ReFacto AF (Xyntha) for Wyeth. For Xyntha/ReFacto AF, it manufactures the pharmaceutical substance in a production process without the addition of any human or animal components.


The company’s customers include patients, healthcare providers, purchasers and pharmacy staff.


Biovitrum AB was founded in 2001.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Swedish Orphan Biovitrum AB Direct Competitors
5.2. Comparison of Swedish Orphan Biovitrum AB and Direct Competitors Financial Ratios
5.3. Comparison of Swedish Orphan Biovitrum AB and Direct Competitors Stock Charts
5.4. Swedish Orphan Biovitrum AB Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Swedish Orphan Biovitrum AB Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Swedish Orphan Biovitrum AB Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Swedish Orphan Biovitrum AB Key Executives
Key Executives Biographies1
Key Executives Compensations1
Swedish Orphan Biovitrum AB Major Shareholders
Swedish Orphan Biovitrum AB History
Swedish Orphan Biovitrum AB Products
Revenues by Segment
Revenues by Region
Swedish Orphan Biovitrum AB Offices and Representations
Swedish Orphan Biovitrum AB SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Swedish Orphan Biovitrum AB Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Swedish Orphan Biovitrum AB Capital Market Snapshot
Swedish Orphan Biovitrum AB Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Swedish Orphan Biovitrum AB Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Swedish Orphan Biovitrum AB Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Swedish Orphan Biovitrum AB Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Swedish Orphan Biovitrum AB 1-year Stock Charts
Swedish Orphan Biovitrum AB 5-year Stock Charts
Swedish Orphan Biovitrum AB vs. Main Indexes 1-year Stock Chart
Swedish Orphan Biovitrum AB vs. Direct Competitors 1-year Stock Charts
Swedish Orphan Biovitrum AB Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Swedish Orphan Biovitrum AB Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: